Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD40L interaction
Open Access
- 1 June 2000
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 105 (11) , 1623-1630
Abstract
The induction of tumor-protective immunity against malignancies remains a major challenge in cancer immunotherapy. A novel, humanized anti-ganglioside-GD2–IL-2 immunocytokine (hu14.18–IL-2) induced CD8+ T cells to eradicate established pulmonary metastases of B78-D14 murine melanoma, in a process that required help by CD4+ T cells and was mediated by the CD40/CD40 ligand (CD40L) interaction. The anti-tumor effect was diminished in mice deficient in CD4+ T-cells. Three lines of evidence show that CD4+ T-cell help was mediated by CD40/CD40L interaction but not by endogenous IL-2 production. First, the hu14.18–IL-2–induced anti-tumor response is partially abrogated in C57BL/6J CD40L knockout (KO) mice in contrast to C57BL/6J IL-2 KO animals, in which the immunocytokine was completely effective. Second, partial abrogation of the anti-tumor effect is induced with anti-CD40L antibodies to the same extent as with CD4+ T-cell depletion. Third, a complete anti-tumor response induced by hu14.18–IL-2 can be reconstituted in C57BL/6J CD40L KO mice by simultaneous stimulation with an anti-CD40 mAb. These results suggest that help provided by CD4+ T cells via CD40/CD40L interactions in our tumor model is crucial for effective immunotherapy with an IL-2 immunocytokine.Keywords
This publication has 42 references indexed in Scilit:
- ImmunocytokinesPharmacology & Therapeutics, 1998
- CD40–CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunitySeminars in Immunology, 1998
- Dendritic Cells, Interleukin 12, and CD4+ Lymphocytes in the Initiation of Class l-restricted Reactivity to a Tumor/Self PeptideCritical Reviews in Immunology, 1998
- Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.Journal of Clinical Investigation, 1996
- The SCID but Not the RAG-2 Gene Product Is Required for Sμ–Sε Heavy Chain Class SwitchingImmunity, 1996
- Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro.Journal of Experimental Medicine, 1996
- T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.Journal of Experimental Medicine, 1996
- Antigen-Presenting Cells: Professionals and amateursCurrent Biology, 1995
- Central Tolerance of T CellsInternational Reviews of Immunology, 1995
- Tolerance, Danger, and the Extended FamilyAnnual Review of Immunology, 1994